Posted by Michael Wonder on 20 Feb 2021
Dynavax announces European Commission marketing authorization for Heplisav B, a two dose adult hepatitis B adjuvanted vaccine
19 February 2021 - Approval based on safety and immunogenicity results from three Phase 3 clinical trials.
Dynavax Technologies today announced that the European Commission has granted marketing authorisation for Heplisav B (hepatitis B vaccine (recombinant), adjuvanted) for the active immunisation against hepatitis B virus infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older.
